Cutaneous T-cell lymphoma (CTCL) research hub
3 indexed studies · 2 currently recruiting
- authorisedTherapeutic exploratory (Phase II)
An Investigator-Initiated, Descriptive, Proof-of-Concept, Open-Label Pilot Study Focusing on Topical JAK Inhibition as a Novel Treatment of Cutaneous T-Cell Lymphoma
This study tests a new medicated cream called Anzupgo for cutaneous T-cell lymphoma, a rare condition causing skin rashes and itching. Researchers want to see if applying this cream for 16 weeks can calm inflammation, clear skin patches, and relieve uncomfortable symptoms in adults with the condition.
Denmark - recruitingTherapeutic exploratory (Phase II)
An Investigator Initiated, descriptive, proof-of-concept, open-label pilot study targeting the tumor microenvironment and skin barrier deficiency through JAK1/3 inhibition
This study is testing a medicine called Xeljanz for a skin condition called Mycosis Fungoides. Doctors want to see if it helps improve the condition by checking how patients respond to the treatment.
Denmark - recruiting
ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
This study aims to better understand advanced Mycosis Fungoides (MF) and Sezary Syndrome (SS), types of skin lymphoma. Researchers are collecting information from patients to identify who might be at higher or lower risk, helping doctors provide better care for these conditions.
United States · Argentina · Australia